selected publications academic article Foxfire, A., Buhrow, A. R., Orugunty, R. S., & Smith, L. (2021). Drug discovery through the isolation of natural products from Burkholderia. Expert Opinion on Drug Discovery. 16(7), 807-822. Barbour, A., Wescombe, P., & Smith, L. (2020). Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases. TRENDS IN MICROBIOLOGY. 28(7), 578-593. Ravichandran, A., Escano, J., Lee, J. H., Ross, M. K., Austin, F., Orugunty, R., Lu, S., & Smith, L. (2020). Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal. Antimicrobial Agents and Chemotherapy. 64(12), e01737-e01720. Ma, J., Guo, F., Jin, Z. i., Geng, M., Ju, M., Ravichandran, A., ... Zhang, H. (2020). Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin. Antimicrobial Agents and Chemotherapy. 64(8), e00244-e00220. Ravichandran, A., Geng, M., Hull, K. G., Li, J., Romo, D., Lu, S., ... Smith, L. (2019). A Novel Actin Binding Drug with In Vivo Efficacy. Antimicrobial Agents and Chemotherapy. 63(1), e01585-aac.01518. Geng, M., Deng, P., Mire, T., Austin, F., & Smith, L. (2019). Draft Genome Sequence of the Lantibiotic-Producing Strain Streptococcus salivarius HS0302. Microbiology Resource Announcements. 8(1), e01410-e01418. Geng, M., Austin, F., Shin, R., & Smith, L. (2018). Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Applied and Environmental Microbiology. 84(5), e02528-e02517. Geng, M., Ravichandran, A., Escano, J., & Smith, L. (2018). Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy. 62(12), aac.01626-aac.01618. Geng, M., & Smith, L. (2018). Improving the attrition rate of Lanthipeptide discovery for commercial applications. Expert Opinion on Drug Discovery. 13(2), 155-167. Geng, M., & Smith, L. (2018). Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability. Applied and Environmental Microbiology. 84(15), e00830-e00818. Smith, J. L. (2011). What have we learned from antibiotics?. Current Pharmaceutical Biotechnology. 12(8), 1183-1183. chapter Gu, J., Smith, J. L., & Dowling, P. K. (2017). Fluorescence In Situ Hybridization Probe Validation for Clinical Use. Methods in Molecular Biology. Cancer Cytogenetics. (pp. 101-118). Springer Nature. conference paper Emrick, D. L., Gosai, J., Graham, V., Smith, J. L., & Gordon, D. M. (2012). Identification of biological pathways that mediate fungal response to occidiofungin exposure. Molecular Biology of the Cell. patent Smith, J. L., & Escano, J. (2022). Modified lantibiotics and methods of making and using the modified lantibiotics Smith, J. L., & Escano, J. (2020). Modified lantibiotics and methods of making and using the modified lantibiotics Smith, J. L., Pruett, S., Austin, F., Lu, S., Akshaya, R., & Laihing, S. (2019). Occidiofungin formations and uses thereof Hillman, J. D., Smith, J. L., & Wilson-Stanford, S. R. (2018). Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features Smith, J., Ravichandran, A., Lu, S., & Gu, G. (2017). Engineering the production of a conformational variant of occidiofungin that has enhanced inhibitory activity against fungal species Hillman, J., Smith, J., & Wilson-stanford, S. (2016). Replacement therapy for dental caries
teaching activities BICH491 Hnr-research Instructor BIOL291 Research Instructor BIOL351 Fund Of Microbiol Instructor BIOL351 Hnr-fund Of Microbiol Instructor BIOL461 Antimicrobial Agents Instructor BIOL491 Hnr-research Instructor BIOL661 Antimicrobial Agents Instructor BIOL685 Directed Studies Instructor BIOL691 Research Instructor GENE491 Hnr-research Instructor
